ScholarIQanswers from OpenAlex & ORCID
Ken H. Young
ResearcherPublications, citations & collaboration network
Ken H. Young is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ken H. Young have?
ScholarIQindexed works
Ken H. Young has 621 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ken H. Young have?
ScholarIQcitation count
Ken H. Young has 27,803 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ken H. Young?
ScholarIQh-index
Ken H. Young has an h-index of 81 in OpenAlex.
What is the i10-index of Ken H. Young?
ScholarIQi10-index
Ken H. Young has an i10-index of 267 in OpenAlex.
What is the ORCID of Ken H. Young?
ScholarIQorcid
The ORCID for Ken H. Young is on the source record.
What is the OpenAlex record for Ken H. Young?
ScholarIQopenalex
The OpenAlex for Ken H. Young is on the source record.
What are the most-cited papers on Ken H. Young?
ScholarIQmost cited works
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov, Tina Green, Lin Wu, Aarthi Balasubramanyam, Wei-min Liu, Carlo Visco, Yong Li, Roberto N. Miranda, Santiago Montes‐Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W.L. Choi, Xiaoying Zhao, J. Han van Krieken, Qin Huang, Jooryung Huh, Weiyun Z. Ai, Maurilio Ponzoni, Andrés J.M. Ferreri, Fan Zhou, Graham W. Slack, Randy D. Gascoyne, Meifeng Tu, Daina Variakojis, Weina Chen, Ronald S. Go, Miguel Á. Piris, Michael Møller, L. Jeffrey Medeiros, Ken H. Young
Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients
Roberto N. Miranda, Tariq N. Aladily, H. Miles Prince, Rashmi Kanagal‐Shamanna, Daphne de Jong, Luis Fayad, Mitual Amin, Nisreen Haideri, Govind Bhagat, Glen S. Brooks, David A. Shifrin, Dennis P. O’Malley, Chan Y. Cheah, Carlos E. Bacchi, Gabrıela Gualco, Shiyong Li, John A. Keech, Ephram P. Hochberg, Matthew J. Carty, Summer E. Hanson, Eid B. Mustafa, Steven Sanchez, John T. Manning, Zijun Y. Xu‐Monette, Alonso R. Miranda, Patricia S. Fox, Roland L. Bassett, Jorge J. Castillo, Brady Beltrán, Jan Paul de Boer, Zaher Chakhachiro, Dongjiu Ye, Douglas Clark, Ken H. Young, L. Jeffrey Medeiros
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang, Luis Fayad, Nicolaus A. Wagner‐Bartak, Liang Zhang, Fredrick Hagemeister, Sattva S. Neelapu, Felipe Samaniego, Peter McLaughlin, Michelle A. Fanale, Anas Younes, Fernando Cabanillas, Nathan Fowler, Kate J. Newberry, Luhong Sun, Ken H. Young, Richard E. Champlin, Larry W. Kwak, Lei Feng, Maria Badillo, Maria Teresa Bejarano, Kimberly Hartig, Wendy Chen, Yi‐Ming Chen, Catriona Byrne, Neda Bell, Jerome B. Zeldis, Jorge Romaguera
miR‐301a as an NF‐κB activator in pancreatic cancer cells
Zhongxin Lu, Yan Li, Yan Li, Apana Takwi, Benhui Li, Jingwen Zhang, Daniel J. Conklin, Ken H. Young, Robert C.G. Martin, Yong Li, Yong Li